Design and optimization of liquisolid compact based vaginal sustained release tablet of antifungal agent for vaginal candidiasis

Kanojiya, Pranita S.; Ghodake, Pradip N.; Wadetwar, Rita N.

doi:10.1080/01932691.2022.2158854

Cited by 8 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For any drug to elicit the desired action, the drug must get solubilized first. 17 Thus, the formation of inclusion complex based tablet helped to overcome the dissolution issue. Generally, the hydrophilic matrix polymers such as HPMC when used in the formulation give the mechanism through the disentanglement and swelling of the polymer.…”

Section: Discussionmentioning

confidence: 99%

“…The similar results were obtained in the study with NLC gel of Voriconazole and Lawsone liquisolid tablet. 1,17 The currently available marketed vaginal medicated products (such as Monistat, Candid V etc.) 28 when applied frequently cause sensation of burning, redness and tingling feeling to the female patients during the course of the treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Where m = weight required for detachment in grams, g = acceleration due to gravity (980 cm/s 2 ) and A = area of the vaginal mucosa exposed. 13,17 Swelling study…”

Section: Ex Vivo Mucoadhesion Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Formulation and Evaluation of Antifungal Drug Containing Mucoadhesive Tablet for Vaginal Candidiasis

Kanojiya,

Wadetwar,

Godbole

2023

Ind. J. Pharm. Edu. Res.

View full text Add to dashboard Cite

Objectives: Female population frequently seeks medical consultation for the vaginal candidiasis. Voriconazole (VOR) is a BCS class II antifungal drug with low aqueous solubility and hence inclusion complex was formulated using Hydroxypropyl-β-cyclodextrin (HPβCD). The complex was incorporated into mucoadhesive vaginal tablet using Chitosan and Hydroxypropyl Methyl Cellulose (HPMC K100). Materials and Methods: A 3 2 full factorial design was employed for sustained release tablet using Design expert® software. Results: Scanning Electron Microscopy (SEM) results indicated the complex formation between the drug and HPβCD. The batches showed 39.68±1.2 to 72.31±1.4% of drug release for 4 hr while for 8 hr it was from 77.23±1.5 to 99.82±1.1%. Therefore, the sustained release of drug was achieved for 8 hr. The tablet batches had swelling % from 228.51±12 to 323.11±8% and mucoadhesive strength from 1131.02±49 to 2302.12±55 dyne/cm 2 . In the in vitro antifungal activity study, a higher zone of inhibition was observed for the inclusion complex-based tablet (34±0.3 mm) as compared to plain drug tablet (25±0.4 mm). Conclusion: Therefore, the inclusion complex-based vaginal tablet could be formulated successfully by employing 3 2 full factorial design for increased residence of drug at the vaginal site of infection and for improved therapeutic efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Formulation and Evaluation of Antifungal Drug Containing Mucoadhesive Tablet for Vaginal Candidiasis

Kanojiya,

Wadetwar,

Godbole

2023

Ind. J. Pharm. Edu. Res.

View full text Add to dashboard Cite

show abstract

Application of Liquisolid Pellets Technology for Improving Dissolution of Posaconazole: A DoE Based Process Optimization

Shah,

Devani,

Dudhat

et al. 2024

J Pharm Innov

View full text Add to dashboard Cite

Improved Dissolution Time and Oral Bioavailability of Pioglitazone Using Liquisolid Tablets: Formulation, In Vitro Characterization, and In Vivo Pharmacokinetics in Rabbits

Swain,

Elhassan,

Bhattacharjee

et al. 2024

ACS Omega

View full text Add to dashboard Cite

In the current study, it was intended to prepare liquisolid tablets of pioglitazone HCl to improve the bioavailability and dissolution time of the drug, as it has low solubility in water. Mathematical formulas were adopted, and the quantities of the carrier (MCC), coating material (colloidal silicon dioxides), and nonvolatile liquid vehicle (Tween 80) were taken. Various ratios of the drug to liquid and carrier to coating had been used in the formulation of liquisolid compacts. The evaluation of the formulated liquisolid compacts was done by performing FTIR, DSC, XRD, and SEM studies. Postcompression parameters, dissolution, stability, and bioavailability were accessed for the optimized formulation. FTIR and DSC studies showed the compatibility of the drugs and excipients. XRD revealed the transition to the amorphous state. It was found that the properties of the newly manufactured liquisolid tablets were within the parameters of what is considered acceptable. The optimized formulation of LST10 showed 99.87 ± 0.19% (p < 0.05) pioglitazone released within 60 min of dissolution. Dissolution data treatments (Q 15 , IDR, RDR, %DE, MDT, f 1 , and f 2 ) resulted in better drug release than other drugs studied and marketed tablet formulations. The optimized formulation produced had been proven stable when it was subjected to accelerated stability testing. This suggested that the bioavailability of pioglitazone was enhanced, as indicated by the substantial increase in AUC 0−t (3.06-fold) and C max (4.18-fold). According to the findings, the selected combination and method significantly increased the dissolution time and bioavailability of pioglitazone. Moreover, this developed method can be used for other drugs with low water solubility.

show abstract

Design and optimization of liquisolid compact based vaginal sustained release tablet of antifungal agent for vaginal candidiasis

Cited by 8 publications

References 34 publications

Formulation and Evaluation of Antifungal Drug Containing Mucoadhesive Tablet for Vaginal Candidiasis

Formulation and Evaluation of Antifungal Drug Containing Mucoadhesive Tablet for Vaginal Candidiasis

Application of Liquisolid Pellets Technology for Improving Dissolution of Posaconazole: A DoE Based Process Optimization

Improved Dissolution Time and Oral Bioavailability of Pioglitazone Using Liquisolid Tablets: Formulation, In Vitro Characterization, and In Vivo Pharmacokinetics in Rabbits

Contact Info

Product

Resources

About